trial · primary record
Adebrelimab
Locally Advanced Resectable Rectal Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 155 |
| Primary completion | 2031-10-31 |
| Primary endpoint | the complete response (CR) rate assessed at the end of Cycle 4 or Cycle 8 |
| Registry ID | NCT07905950 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:37.867Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07905950
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Adebrelimab · compound